Taltz Purple Book BLA 125521

BLA number
125521
Proprietary names
Taltz
Proper names
ixekizumab
Applicant
Eli Lilly and Company
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Taltzixekizumab351(a)80MG/MLInjectionSubcutaneousAutoinjectorRxLicensed2016-03-22
002Taltzixekizumab351(a)80MG/MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2016-03-22
003Taltzixekizumab351(a)40MG/0.5MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2024-08-20
004Taltzixekizumab351(a)20MG/0.25MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2024-08-20

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2024-08-01N003Taltz351(a)RxEli Lilly and Company
2024-08-01N004Taltz351(a)RxEli Lilly and Company
2020-05-01R001Taltz351(a)RxEli Lilly and Company
2020-05-01R002Taltz351(a)RxEli Lilly and Company

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2024-08-01003Taltz351(a)RxLicensed2024-08-20
2024-08-01004Taltz351(a)RxLicensed2024-08-20
2020-05-01001Taltz351(a)RxLicensed2016-03-22
2020-05-01002Taltz351(a)RxLicensed2016-03-22